EQT in advanced talks to acquire Qiagen for over $10bn
EQT is in advanced negotiations to acquire European molecular testing company Qiagen in a potential buyout valued at more than $10bn, with rival private equity firm KKR also submitting a bid, according to a report by Bloomberg.
EQT is engaged in advanced talks to acquire Qiagen, a European molecular testing company, in a potential transaction valued at over $10 billion, according to Bloomberg. KKR, a rival private equity firm, has also submitted an offer for Qiagen. The Swedish buyout manager has reportedly presented a binding bid exceeding $50 per share for Qiagen, and the company's board is set to meet this week to evaluate the offer.
Qiagen's US-listed shares surged up to 9.2% following the report on Tuesday, suggesting a market valuation of approximately $10.2 billion. The company is also listed on the Frankfurt stock exchange. A successful acquisition would mark one of Europe's largest healthcare buyouts this year, concluding years of takeover speculation surrounding the diagnostics firm.
Qiagen, based in the Netherlands, develops molecular testing technologies utilized in clinical diagnostics, pharmaceutical research, and life sciences. The company has been exploring strategic alternatives amid renewed buyout interest, with Bloomberg reporting in January that Qiagen was considering its options. However, discussions with EQT or any other potential bidder remain ongoing, and there is no certainty that a transaction will materialize.
Written by urgent.news from Private Equity Wire's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
